Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Clinical outcomes of patients with or without common AEs in anlotinib cohort: Subgroup analysis of the ALTER0303 trial.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20507

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20507)

Author(s): Wang Zhe-Hai, Baohui Han, Kai Li, Ying Cheng, Jie Liu, Jun Guo, Liyan Liu, Chao Xie, Xiao Han, Haiyong WANG, Qiming Wang, Li Zhang, Jianhua Shi, Jianxing He, Yuankai Shi, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Kejun Nan, Anlotinbi authors' group; Shandong Cancer Hospital, Shangdong, China; Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China; Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Oncology, Jilin Province Cancer Hospital, Changchun, China; Shandong Cancer Hospital, Jinan, China; Henan Cancer Hospital, Zhengzhou, China; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Shandong Linyi Tumor Hospital, Linyi, China; The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; Lanzhou Military General Hospital, Lanzhou, China; Hunan Cancer Hospital, Changsha, China; Department of Thoracic Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University (Hunan Cancer Hospital), Changsha, China; Qilu Hospital of Shandong University, Jinan, China; The First Affiliated Hospital of Xi'An Jiaotong University, Xi'an, China

Abstract Disclosures

Abstract:

Background: In ALTER 0303, the common adverse reaction (AE) included hypertension (HTN) and hand foot syndrome (HFS). In this subgroup analysis, we aim to assess the relationship between common AEs and clinical benefit in anlotinib cohort. Methods: Eligible patients showed disease progression after second-line or further treatment were randomly assigned in a 2:1 ratio to receive 12 mg/day of anlotinib or placebo. The primary endpoint was overall survival (OS). This subgroup analysis was based on anlotinib cohort. Results: Patients with HTN had significantly improved median OS, median progress-free survival (PFS), objective response (ORR) and disease control rate (DCR) compared with patients without HFS in anlotinib cohort. Similarly, patients with HFS had better clinical outcomes in anlotinib cohort. Not surprisingly, patients occurred both HFS and HTN had more superior medium OS compared with only HFS, only HTN and neither HFS nor HTN. Conclusions: HTN or HFS is associated with better clinical outcomes in advanced NSCLC patients received anlotinib. Clinical trial information: NCT02388919

Clinical outcomes of patients with or without common AEs in anlotinib cohort.

Clinical outcomesWith HTN
N = 199
Without HTN
N = 95
HR or OR (95%CI)P value
mOS, months10.706.870.64 (0.48, 0.87)0.001
mPFS, months5.703.230.49 (0.36, 0.67)0.000
ORR, %12.063.164.21 (1.23, 14.34)0.016
DCR, %88.4465.264.07 (2.22, 7.47)0.000
With HFS
N = 129
Without HFS
N = 165
HR or OR (95%CI)P value
mOS, months14.507.330.50 (0.37, 0.68)0.000
mPFS, months5.774.230.49 (0.37, 0.65)0.000
ORR, %13.955.452.81 (1.22, 6.49)0.015
DCR, %94.5770.307.36 (3.21, 16.91)0.000

Cox regression adjusted for gender, age, ECOG PS, number of metastatic sites. OR = Odds Ratio HR = Hazard Ratio

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...